AstraZeneca tops quarterly estimates excited by most cancers medicine

Firm raises full yr adjusted EPS forecast Complete oncology product portfolio gross sales up 24% Shares rose practically 2% in early commerce Nov 10 (Reuters) – AstraZeneca (AZN.L) on Thursday raised its full-year adjusted earnings forecast following analysts’ expectations for third-quarter revenue and income, helped by gross sales of its key most cancers medicine. Oncology … Read more